Serono received approval from the European Commission for an update of the Summary of Product Characteristics (SmPC) of Rebif, in order to align it with current medical practice. In the EU, Rebif can now be prescribed after the diagnosis of multiple sclerosis (MS) has been confirmed based on one attack and subsequent positive magnetic resonance imaging (MRI) scans. The ‘therapeutic indication’ section of the SmPC of Rebif now takes into account the McDonald criteria, which are t...